---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-097951"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2026-08-17T21:28:26+00:00"
generated_at: "2026-08-17T21:30:11.673920+00:00"
event_type: "dividend"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coherus declares special CVR dividend for legacy biosimilar asset proceeds

## Summary
- One CVR per share of common stock; record date Sept 30, 2026, distribution Oct 7, 2026.
- CVRs entitle holders to net cash proceeds from sale/licensing of Legacy BioSim Assets (patents, IP, royalties, cell lines).
- CVRs non-transferable, no trading market, expire Oct 7, 2028; no guaranteed payment.
- Company retained investment bank as capital markets advisor for sale process; Loan Agreement with Innovatus Life Sciences restricts dispositions.
- CVRs not certificated, no voting rights, no interest; tax treatment uncertain.

## SEC filing metadata
- accession: 0001104659-26-097951
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2026-08-17T21:28:26+00:00
- event_type: dividend
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000110465926097951/0001104659-26-097951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000110465926097951/chrs-20260817x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-097951
- JSON: https://secwatch.observer/filing/0001104659-26-097951.json
- Plain text: https://secwatch.observer/filing/0001104659-26-097951.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.